Search results for "IDH"

showing 10 items of 21 documents

Glomales species associated with surface and deep rhizosphere of Faidherbia albida in Senegal

2000

Five arbuscular mycorrhizal (AM) fungal species were isolated and propagated from surface and deep rhizospheres of Faidherbia albida trees growing in two ecoclimatic zones of West Africa: the semi-arid Sahelian and the more humid Sudano-Guinean areas. Of these species, Glomus aggregatum, Glomus caledonium, and Glomus mosseae were trapped by F. albida roots when cultivated with either surface or deep soils. Glomus fasciculatum was found exclusively at the semi-arid Sahelian sites of Louga and Diokoul and Gigaspora margarita was isolated only from 16.5-m and 34-m-deep samples. Comparable glomalean fungal species richness was identified in deep (1.5–34 m) and surface (0.15 m) samples. The isol…

0106 biological sciencesPlant ScienceBiology01 natural sciencesGLOMALESSymbiosisBotanyGeneticsMycorrhizaMultipurpose treeMolecular Biology[SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/MycologyEcology Evolution Behavior and SystematicsGlomusComputingMilieux_MISCELLANEOUSRhizosphere04 agricultural and veterinary sciencesGeneral Medicine15. Life on landbiology.organism_classification[SDV.MP.MYC] Life Sciences [q-bio]/Microbiology and Parasitology/MycologyFaidherbia albida040103 agronomy & agriculture0401 agriculture forestry and fisheriesGlomus aggregatumSpecies richness010606 plant biology & botany
researchProduct

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment

2021

Despite impressive and durable responses, nonsmall cell lung cancer (NSCLC) patients treated with anaplastic lymphoma kinase (ALK) inhibitors (ALK‐Is) ultimately progress due to development of resistance. Here, we have evaluated the clinical utility of circulating tumor DNA (ctDNA) profiling by next‐generation sequencing (NGS) upon disease progression. We collected 26 plasma and two cerebrospinal fluid samples from 24 advanced ALK‐positive NSCLC patients at disease progression to an ALK‐I. These samples were analyzed by NGS and digital PCR. A tool to retrieve variants at the ALK locus was developed (VALK tool). We identified at least one resistance mutation in the ALK locus in ten (38.5%) p…

0301 basic medicineCancer ResearchLung NeoplasmsEML4-ALKAntineoplastic AgentsEML4‐ALKmedicine.disease_causeNSCLCIDH2Circulating Tumor DNA03 medical and health sciencesALK-TKI0302 clinical medicineCarcinoma Non-Small-Cell LungMAP2K1hemic and lymphatic diseasesALK‐TKIGeneticsmedicineHumansAnaplastic lymphoma kinaseAnaplastic Lymphoma KinaseDigital polymerase chain reactionPrecision MedicineLiquid biopsyProtein Kinase InhibitorsneoplasmsResearch ArticlesRC254-282MutationCrizotinibliquid biopsybusiness.industryHigh-Throughput Nucleotide SequencingNeoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineResistance mutation3. Good health030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisNGSMutationCancer researchMolecular MedicinebusinessResearch Articlemedicine.drugMolecular Oncology
researchProduct

Quantitative Imaging of D-2-Hydroxyglutarate in Selected Histological Tissue Areas by a Novel Bioluminescence Technique

2016

Abstract Patients with malignant gliomas have a poor prognosis with average survival of less than one year. Whereas in other tumor entities the characteristics of tumor metabolism are successfully used for therapeutic approaches, such developments are very rare in brain tumors, notably in gliomas. One metabolic feature characteristic of gliomas, in particular diffuse astrocytomas and oligodendroglial tumors, is the variable content of D-2-hydroxyglutarate (D2HG), a metabolite, which was discovered first in this tumor entity. D2HG is generated in large amounts due to various “gain-of–function” mutations in the isocitrate dehydrogenases IDH-1 and IDH-2. Meanwhile, D2HG has been detected in se…

0301 basic medicineCancer ResearchPathologymedicine.medical_specialtyMetabolite610 MedizinBiology03 medical and health scienceschemistry.chemical_compoundmedicineBioluminescence imagingBioluminescenceOligodendroglial TumorOriginal Researchddc:610D-2 hydroxyglutarateglioblastomaMyeloid leukemiaCancerACUTE MYELOID-LEUKEMIA; ISOCITRATE DEHYDROGENASE 1; IDH2 MUTATIONS; CHROMATOGRAPHY/MASS SPECTROMETRY; MAGNETIC-RESONANCE; 2-HYDROXYGLUTARATE; CANCER; GLIOMAS; L-2-HYDROXYGLUTARATE; METABOLITES; D-2 hydroxyglutarate; IDH mutations; bioluminescence imaging; oncometabolite; glioblastomabioluminescence imagingIDH mutationsmedicine.diseaseoncometaboliteLymphoma030104 developmental biologychemistryOncologyChondrosarcoma
researchProduct

Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma.

2019

Glioblastoma (GBM) is the most common malignant primary tumor of the central nervous system. With no effective therapy, the prognosis for patients is terrible poor. It is highly heterogeneous and EGFR amplification is its most frequent molecular alteration. In this light, we aimed to examine the genetic heterogeneity of GBM and to correlate it with the clinical characteristics of the patients. For that purpose, we analyzed the status of EGFR and the somatic copy number alterations (CNAs) of a set of tumor suppressor genes and oncogenes. Thus, we found GBMs with high level of EGFR amplification, low level and with no EGFR amplification. Highly amplified tumors showed histological features of…

0301 basic medicineMaleCancer ResearchBiopsyL-amp GB EGFR-low amplified glioblastomamedicine.disease_causewt wildtypeMYBPC3 myosin-binding protein C0302 clinical medicineHIC1 hypermethylated in cancer 1Gene duplicationIn Situ Hybridization FluorescenceIDH2 isocitrate dehydrogenase 2MutationRB-pat RB signaling pathwayEGFRvIII epidermal growth factor receptor variant number IIIPAH phenylalanine hydroxylaseGBM glioblastoma IDH-wildtype (glioblastoma multiforme primary glioblastoma).ANOVA ANalysis Of VArianceN-amp GB EGFR-no amplified glioblastomaMiddle AgedCDKN2A cyclin-dependent kinase inhibitor 2Alcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisPrimary tumorImmunohistochemistryH-amp GB EGFR-high amplified glioblastomaErbB ReceptorsTKR-pat tyrosine-kinase receptors signaling pathway030220 oncology & carcinogenesisDisease ProgressionCDK6 cyclin-dependent kinase 6CDH1 Cadherin 1FemaleCREM cAMP response element modulatorIHC immunohistochemistryAdultOriginal articleDNA Copy Number VariationsCDKN1B cyclin-dependent kinase inhibitor 1BBiologyRARB retinoic acid receptor betaCNS central nervous systemlcsh:RC254-282IDH1 isocitrate dehydrogenase 1BCL2 B-cell cll/ lymphoma 2CNAs copy number algerationsWHO World Health Organization03 medical and health sciencesYoung Adultp53-pat p53 signaling pathwaymedicineBiomarkers TumorTMA tissue microarrayPTENHumansProtein kinase BPI3K/AKT/mTOR pathwaySurvival analysisAgedGenetic heterogeneityGene AmplificationGFAP glial fibrillary acidic proteinMLPA multiplex ligation-dependent probe amplificationmedicine.diseaseFISH fluorescence in situ hibridizationSurvival AnalysisCDKN2B cyclin-dependent kinase inhibitor 2BPTEN phosphatase and tensin homologEGFR epidermal growth factor receptorCNV-load load of copy number variations030104 developmental biologyMutationPARK2 parkinCancer researchbiology.proteinTCGA The Cancer Genome AtlasLARGE1 acetylglucosaminyltransferase-like protein 1GlioblastomaCHD7 Chromodomain Helicase DNA Binding Protein 7DAPI 4′6-diamidino-2-phenylindoleNeoplasia (New York, N.Y.)
researchProduct

WHO-defined ‘myelodysplastic syndrome with isolated del(5q)’ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence …

2010

The 2008 World Health Organization (WHO) criteria were used to identify 88 consecutive Mayo Clinic patients with 'myelodysplastic syndrome with isolated del(5q)' (median age 74 years; 60 females). In all, 60 (68%) patients were followed up to the time of their death. Overall median survival was 66 months; leukemic transformation was documented in five (5.7%) cases. Multivariable analysis identified age >or=70 years (P=0.01), transfusion need at diagnosis (P=0.04) and dysgranulopoiesis (P=0.02) as independent predictors of shortened survival; the presence of zero (low risk), one (intermediate risk) or >or=2 (high risk) risk factors corresponded to median survivals of 102, 52 and 27 months, r…

AdultMaleCancer Researchmedicine.medical_specialtyIDH1Biology5q-World Health OrganizationPolymerase Chain ReactionGastroenterologyIDH2ironInternal medicineMyelodysplastic Syndrome with Isolated del(5q)medicineHumansSurvival rateAgedAged 80 and overThrombopoietin receptorHematologyMyelodysplastic syndromesferritinHematologyJanus Kinase 2Middle AgedPrognosismedicine.diseaseIsocitrate DehydrogenaseSurvival RateLeukemiaCell Transformation NeoplasticOncologyMyelodysplastic SyndromesMutationImmunologyChromosomes Human Pair 5Original ArticleFemaleChromosome DeletionReceptors ThrombopoietinLeukemia
researchProduct

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol

2022

Simple Summary IDH1/2 mutations are a common event in acute myeloid leukemia (AML) and represent a therapeutic target. We designed the GIMEMA AML1516 observational protocol to examine the prevalence of IDH1/2 mutations and the associations between IDH mutations and clinico-biological parameters in a cohort of Italian patients affected by AML. By analyzing 284 consecutive adult AML patients, we confirmed that IDH1 and IDH2 mutations are frequently detected-14% and 18%, respectively-at diagnosis. IDH1/2 mutations were significantly associated with an inferior performance status and non-complex karyotype when compared to IDH1/2-WT. With regards to the outcome, in the subset of IDH1/2-mutated p…

DH1Cancer ResearchOncologyAMLAML DH1 IDH2 prevalence prognosisprevalenceIDH2prognosisSettore MED/15AML; DH1; IDH2; prevalence; prognosis
researchProduct

D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.

2014

Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) have been discovered in several cancer types and cause the neurometabolic syndrome D2-hydroxyglutaric aciduria (D2HGA). The mutant enzymes exhibit neomorphic activity resulting in production of D2-hydroxyglutaric acid (D-2HG). To study the pathophysiological consequences of the accumulation of D-2HG, we generated transgenic mice with conditionally activated IDH2R140Q and IDH2R172K alleles. Global induction of mutant IDH2 expression in adults resulted in dilated cardiomyopathy, white matter abnormalities throughout the central nervous system (CNS), and muscular dystrophy. Embryonic activation of mutant IDH2 resulted in more pronounced ph…

Genetically modified mouseTransgeneMutantCardiomyopathyMice NudeBiologyIDH2Cell LineGlutarateschemistry.chemical_compoundMiceGeneticsmedicineAnimalsHumansMuscular dystrophyMice Inbred BALB CGlycogenGene Expression ProfilingGene Expression Regulation DevelopmentalHeartNeurodegenerative Diseasesmedicine.diseaseMolecular biologyIsocitrate DehydrogenaseIsocitrate dehydrogenasechemistryMutationCardiomyopathiesDevelopmental BiologyResearch PaperGenesdevelopment
researchProduct

Caracterización molecular de las leucemias mieloides agudas de novo

2013

La secuenciación es la técnica de elección para identificar mutaciones. Sin embargo, tiene un coste elevado, es laboriosa y su sensibilidad es limitada. Recientemente, el nuevo método de análisis de alta resolución con curvas de fusión (High Resolution Melt, HRM) permite detectar de forma rápida y específica mutaciones, polimorfismos y cambios epigenéticos. La leucemia mieloide aguda (LMA) son enfermedades heterogéneas con distintos comportamientos clínicos. El 40-50% de los pacientes no presentan alteraciones cromosómicas específicas y los mecanismos moleculares que subyacen en su patogenia son en su mayor parte desconocidos. Avances en la caracterización molecular han permitido la identif…

IDHLMA de novoUNESCO::CIENCIAS DE LA VIDADNMT3AC-CBLASXL1:CIENCIAS DE LA VIDA [UNESCO]
researchProduct

Identification of New Genetic Clusters in Glioblastoma Multiforme: EGFR Status and ADD3 Losses Influence Prognosis

2020

Glioblastoma multiforme (GB) is one of the most aggressive tumors. Despite continuous efforts to improve its clinical management, there is still no strategy to avoid a rapid and fatal outcome. EGFR amplification is the most characteristic alteration of these tumors. Although effective therapy against it has not yet been found in GB, it may be central to classifying patients. We investigated somatic-copy number alterations (SCNA) by multiplex ligation-dependent probe amplification in a series of 137 GB, together with the detection of EGFRvIII and FISH analysis for EGFR amplification. Publicly available data from 604 patients were used as a validation cohort. We found statistical associations…

IDHMaleOncologymedicine.medical_specialtyDNA Copy Number VariationsEGFRSCNAsurvivalArticleText miningCDKN2AInternal medicineHumansMedicineMultiplexlcsh:QH301-705.5<i>IDH</i>Brain Neoplasmsbusiness.industryGene AmplificationglioblastomaGeneral MedicineMiddle AgedADD3Prognosismedicine.diseaseSurvival AnalysisErbB ReceptorsMSH6high throughout techniqueslcsh:Biology (General)ADD3Multigene FamilyCalmodulin-Binding ProteinsFemaleprecisionIdentification (biology)businessSignal TransductionGlioblastomaCells
researchProduct

Forecasting Molecular Features in IDH-Wildtype Gliomas: The State of the Art of Radiomics Applied to Neurosurgery

2023

Simple Summary The prognostic expectancies of patients affected by glioblastoma have remained almost unchanged during the last thirty years. Along with specific oncological research and surgical technical alternatives, corollary disciplines are requested to provide their contributions to improve patient management and outcomes. Technological improvements in radiology have led to the development of radiomics, a new discipline able to detect tumoral phenotypical features through the extraction and analysis of a large amount of data. Intuitively, the early foreseeing of glioma features may constitute a tremendous contribution to the management of patients. The present manuscript analyzes the p…

IDHWHO classificationCancer ResearchOncologyEGFRradiomicglioblastomaTERTpaneuploidiebrain tumorCancers
researchProduct